| Recruiting | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling NCT05857969 | Florida International University | Phase 1 |
| Completed | Ex Vivo Drug Sensitivity Testing and Mutation Profiling NCT03860376 | Florida International University | — |
| Completed | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly NCT03526250 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors NCT03387020 | Pediatric Brain Tumor Consortium | Phase 1 |
| Completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumo NCT02684071 | Nicklaus Children's Hospital f/k/a Miami Children's Hospital | Phase 2 |
| Active Not Recruiting | Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diff NCT02359565 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Everolimus for Children With Recurrent or Progressive Ependymoma NCT02155920 | University of Texas Southwestern Medical Center | Phase 2 |
| Withdrawn | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors NCT02194452 | Sue O'Dorisio | N/A |
| Completed | Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or E NCT01462695 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS T NCT01088763 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spi NCT01076530 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Cent NCT00994500 | National Cancer Institute (NCI) | Phase 1 |
| Completed | ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors NCT00946335 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagn NCT00638898 | City of Hope Medical Center | Phase 1 |
| Completed | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medul NCT00381797 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma NCT00363272 | National Cancer Institute (NCI) | Phase 1 |
| Completed | AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors NCT00326664 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas NCT00101270 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors NCT00100880 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors NCT00095940 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatme NCT00091182 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors NCT00919750 | Children's Oncology Group | — |
| Completed | Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors NCT00077454 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cilengitide in Treating Children With Refractory Primary Brain Tumors NCT00063973 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors NCT00052780 | National Cancer Institute (NCI) | Phase 1 |
| Completed | FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia NCT00053963 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas NCT00012181 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Irinotecan in Treating Children With Refractory Solid Tumors NCT00004078 | Children's Oncology Group | Phase 2 |